New perspectives in the management of small cell lung cancer

Table 2 Thoracic radiotherapy and stereotactic body radiotherapy in early-stage small cell lung cancer

Ref.	Sample size	Fractionation	QT	Prophylactic cranial irradiation	Local control	Overall survival	Disease-free survival
Videtic et al[76], 2013	n = 6	60 Gy (3 fx); 50 Gy (5 fx); 30 Gy (1 fx)	4/6	4/6	100% (1 yr)	63% (1 yr)	75% (1 yr)
Shioyama et al[77], 2015	n = 64	48 Gy (4 fx)	36/64	10/64	89% (2 yr)	76% (2 yr)
Stahl et al[79], 2017	n = 285	48-60 Gy (3-5 fx)	130/285		35% (3 yr). 21.5% (5 yr)
Verma et al[75], 2017	n = 74	50 Gy (5 fx)	45/74	17/74	96% (3 yr)
Shioyama et al[78], 2018	n = 43	36-60 Gy (3-10 fx)	8/43	8/43	80.2% (2 yr)	72.3% (2 yr)	44.6% (2 yr)
Verma et al[74], 2019	n = 149	45-60 Gy (3-8 fx)	149/149		83.8% (29.2 mo)
Newman et al[81], 2019	n = 239	BED > 100 Gy (max 8 fx)	84/239		27% (5 yr); 36% (5 yr, with QT)
Singh et al[80], 2019	n = 21	BED 105.6 Gy (3-5 fx)	4/21		100% (1, 2, 3 yr)	73.1% (1 yr); 36.6% (2 yr)	85.7% (1 yr); 42.9% (2 yr)

BED: Biologically equivalent dose; fx: Fraction; QT: Chemotherapy.